I can understand but if they don't that will be considered as broken promise.Too early to make future projections imo.
At this stage they'd have may be a slight idea, but it's dangerous to make projections if unsure.
If they make a projection and couldn't keep up with it for whatever reason, market won't take it kindly.
I think its fair to say that mgt has pretty much kept to the technical development schedule. The inital delay in releasing AKD1000 was to incorporate customer requests so that's understandable and acceptable.I can understand but if they don't that will be considered as broken promise.
That also means that the progress is much slower than management anticipation.
That also means all those shares( options) issued on meeting target are not accurate or someone in the team is unable to perform as per expectations.
So to me it poses more questions.
Upto now I believe brainchip management is very good and they come out good on their promises. If they don't want to provide us with forward statements that will mean a broken promise.
I don't think management was over bullish. When you look at transactions of PVDM share sale I can tell you he is genuine person. To me it might be the tech slow down but even that should not had effected brn as it is a very new technology.I think its fair to say that mgt has pretty much kept to the technical development schedule. The inital delay in releasing AKD1000 was to incorporate customer requests so that's understandable and acceptable.
What's less satisfactory is the extending of the commercialisation schedule. Its pretty clear that mgt did not anticipate the lengthy sales cyccle of an innovative new technology that few product developers were in fact ready for. The "broken promises" indicate to me that mgt was overly optimistic in its assessment of time to market. Their seemingly misplaced optimism is perhaps one of the reasons for the lack of detail around sales progress. Who wants to admit they're wrong when they are supposed to be experts in the field..............
Just my randon thoughts............
That's the plan, but I'll wait for a few more days if something comes up I can send 1 email after formatting all questions without double up.Perhaps we should draw this thread to the attention of TD and he could create a list of questions to Sean Hehir and others to address on AGM day. Or, maybe this has already been done by others.
TD will be seeing these posts!!That's the plan, but I'll wait for a few more days if something comes up I can send 1 email after formatting all questions without double up.
They can either;
- reply to me via email which I will share here on TSE.
- address these on AGM (my preference. This way they can address questions officially to the market and not 2000 shareholders here on TSE).
- or as alwaysgreen suggested, do a podcast with Sean addressing these questions.
That is broad level understanding. And we all assumes the same.My understanding is Akida IP can only be in Megachips and Renesas products because they have a licence agreement. No other products can be sold until a licence is signed. NDA or Not. And it must be a material announcement on asx. Would this be correct???
Not sure how to frame this question correctly. It would put a lot of rumoured products that we are already in to rest. I've been guilty of this myself..
It has been resolved on some platforms per some posters(Ameritrade ??? ...), and not on others. I trade on Fidelity, a tiny rinky dink operation (I'm obviously JOKING....they are HUGE), and they still have in place the $50 foreign transaction fee that is an annoying $50 toll (fee) that they charge coming (buying) or going (selling) and regardless of the size of the trade. But I invest in BRCHF, as opposed to BCHPY. Vanguard does not allow trading in BRCHF shares any more, as far as I know.Morning Chippers,
Another question to put forth..
This issue may have been addressed, if so please disregard.
Concerning our American listed ADR's ( 40:1 ).
Code : BCHPY.
Has the EXTRA cost of purchasing this stock been resolved for American buyers, if not why not as this issue was raised some time ago. Naturally I have forgotten what this extra fee is called.
Non-existent trade in this is somewhat confusing as this was supposed to open us up to a far larger investing audience.
Like I said , this issue may have been resolved.
If one of our American share holders could comment on this issue will help decide if this issue should be put forth to Management , again.
Regards,
Esq.
I never had an issue with getting ADR shares in my account cost me 9 dollars a trade. It took a while to accumulate the shares they are thinly traded and purchases affect then end goal.Morning Chippers,
Another question to put forth..
This issue may have been addressed, if so please disregard.
Concerning our American listed ADR's ( 40:1 ).
Code : BCHPY.
Has the EXTRA cost of purchasing this stock been resolved for American buyers, if not why not as this issue was raised some time ago. Naturally I have forgotten what this extra fee is called.
Non-existent trade in this is somewhat confusing as this was supposed to open us up to a far larger investing audience.
Like I said , this issue may have been resolved.
If one of our American share holders could comment on this issue will help decide if this issue should be put forth to Management , again.
Regards,
Esq.
Great question MD .... That would be the icing on the cake IMO .... great exposure and will become the 'Norm' in most households/Factories/cars etc ....... Sorry guys but I'm afraid I'm going to have to post it again!!!Agm question i guess -
Will we ba able to see the Akida trademark on products just like intels trademark? If the product is being powered by Brainchip Akida technology would i be correct that it will at the very least on the packaging?